ARTICLE | Company News
Calgene news
February 7, 1994 8:00 AM UTC
CGNE (Davis, Calif.) said delays in FDA clearance of its genetically engineered Flavr Savr tomato will exert considerable cost pressure on the company, which must support the infrastructure it put in place in expectation of product sales. As a result, CGNE said it expects to incur a larger loss in fiscal 1994 than the $25.6 million loss in fiscal 1993. ...